52506-21-5

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 8-oxo-1,4-dioxaspiro[4.5]decane-7-carboxylate is utilized as a key intermediate in the synthesis of various drugs and pharmaceutical products. Its unique molecular architecture and reactivity make it a valuable component in the development of new medications with diverse therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, methyl 8-oxo-1,4-dioxaspiro[4.5]decane-7-carboxylate is employed as a versatile building block for creating a range of organic compounds. Its interesting molecular structure and properties allow for the exploration of novel synthetic pathways and the creation of new chemical entities.
Used in Chemical Research:
Methyl 8-oxo-1,4-dioxaspiro[4.5]decane-7-carboxylate also finds application in chemical research, where its unique structure and properties are studied to gain insights into the behavior of spirocyclic compounds and to develop new methodologies for organic synthesis and compound design.

Upstream product

• 86488-09-7 4-ethylenedioxy-1,7-heptanedionic acid, dimethyl ester 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 616-38-6 carbonic acid dimethyl ester 

Downstream Products

• 144344-89-8 7-(4-Acetoxy-benzyl)-8-oxo-1,4-dioxa-spiro[4.5]decane-7-carboxylic acid methyl ester 
• 114506-25-1 C₃₀H₃₂O₉S 
• 86119-05-3 5'-methyl-6'-oxo-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalene]-8'a-carboxylic acid methyl ester 
• 149764-75-0 5'-[(Dimethyl-phenyl-silanyl)-methyl]-1',3',4',7',8',8'a-hexahydro-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-one 
• 145315-73-7 2,3,4,4a,5,6,7,8-octahydro-1-<(dimethylphenylsilyl)methyl>-4a-<(methyloxy)carbonyl>-6,6-(ethylenedioxy)-2(1H)-naphthalenone 
• 145315-75-9 5'-[(Methyl-diphenyl-silanyl)-methyl]-1',3',4',7',8',8'a-hexahydro-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-one 
• 145315-74-8 5'-[(Methyl-diphenyl-silanyl)-methyl]-6'-oxo-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalene]-8'a-carboxylic acid methyl ester 
• 145315-76-0 5'-[(tert-Butyl-diphenyl-silanyl)-methyl]-1',3',4',7',8',8'a-hexahydro-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-one 
• 149765-13-9 5'-[(tert-Butyl-diphenyl-silanyl)-methyl]-6'-oxo-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalene]-8'a-carboxylic acid methyl ester 
• 874360-02-8 methyl 8-(2,4,5-trifluorophenyl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate 
• 874360-03-9 methyl 8-(2,4,5-trifluorophenyl)-1,4-dioxaspiro[4.5]decane-7-carboxylate 
• 874360-01-7 benzyl [(1S,2R)-5-oxo-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate 

Relevant academic research and scientific papers

Synthesis of the 4-azatricyclo[5.2.2.04,8]undecan-10-one core of Daphniphyllum alkaloid calyciphylline A using a Pd-catalyzed enolate alkenylation

(Chemical Equation Presented) The ABC ring system of the natural product calyciphylline A has been synthesized. The key steps were a palladium-catalyzed intramolecular coupling of an amino-tethered vinyl bromide with a ketone using potassium phenoxide as

Stereoselective synthesis of C-6 hydroxy tricyclic sulfone as a γ-secretase inhibitor

The synthesis of a C-6 hydroxy tricyclic sulfone was described with two key reactions: the Suzuki coupling and the regioselective and stereoselective cis ring opening of the epoxide. Overall, the 14-step synthesis was achieved in 2.1% yield.

Synthetic method of huperzine A

The invention belongs to the technical field of medicine synthesis and particularly relates to a synthetic method of huperzine A. The method includes twelve steps of reactions, 1,4-dioxaspiro[4.5]decan-8-one being a raw material, so that the chemical synthesis of the huperzine A is completed at a high total yield. The method is fewer in reaction steps, is simple in operations, has high yield, is stable in intermediates and gentle in reaction conditions, and is easy to control in reactions.

Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator that promotes the transcription of cytoprotective genes in response to oxidative/electrophilic stress. Various Michael-type compounds were designed and synthesized, and their potency

Iridium-catalyzed asymmetric hydrogenation of α-substituted α,β-unsaturated acyclic ketones: Enantioselective total synthesis of (-)-mesembrine

A highly efficient asymmetric hydrogenation of α-substituted α,β-unsaturated acyclic ketones catalyzed by chiral spiro iridium complexes for the preparation of chiral 2-substituted allylic alcohols has been developed (ee up to 99.7%). This method provides a concise route to (-)-mesembrine (34% yield, 12 steps).

OXASPIRO [2.5] OCTANE DERIVATIVES AND ANALOGS

The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.

TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted tricyclic heteroaromatic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin

Molecular modeling was used to design a rigid analog of sitagliptin 1. The X-ray crystal structure of sitagliptin bound to DPP-4 suggested that the central β-amino butyl amide moiety could be replaced with a cyclohexylamine group. This was confirmed by structural analysis and the resulting analog 2a was synthesized and found to be a potent DPP-4 inhibitor (IC50 = 21 nM) with excellent in vivo activity and pharmacokinetic profile.

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Studies on the synthesis of Schisandraceae natural products: Exploring a cyclopropylcarbinol ring expansion strategy

Acid mediated cyclopropylcarbinol ring expansion has been shown to be a viable method for the construction of the AB ring framework of lancifodilactone F and related terpenoids of the Schisandraceae family of natural products. We found that this rearrangement proceeds with good stereochemical control based on inversion of the C10 cyclopropyl center. Our studies indicate that the cis-decalin motif of 31 could be used as a key synthetic precursor of certain Schisandraceae metabolites. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.